EQUITY RESEARCH - ANALYST MEETING



BUMRUNGRAD HOSPITAL BH TB

THAILAND / HEALTH CARE SERVICES

BUY

UNCHANGE

TARGET PRICE CLOSE UP/DOWNSIDE PRIOR TP CHANGE IN TP

TP vs CONSENSUS

THB220.00 THB195.50 +12.5% THB220.00 UNCHANGED -10.9%

Key takeaways from analyst meeting

- Overall tone is negative, but relatively in line with our expectation.
- Management provided more details about the revenue breakdown by segment in 4Q24. International patient revenue dropped by 7% y-y mainly due to the 19% y-y decrease in the Middle East market. Meanwhile, revenue from the Indochina market grew by 1% y-y and other markets (including USA and China) grew by 9% y-y.
- Revenue from Kuwaiti and UAE patients was still weak and dropped by 73% y-y and 37% y-y, respectively, in 4Q24. Overall, Kuwaiti and UAE patient revenue decreased by THB1.2b (THB0.9b for Kuwait and THB0.3b for UAE) in 2024, which accounted for 5% of 2024 revenue. The Kuwaiti patient revenue contribution declined to 1% in 4Q24 and 2% in 2024 (vs 5% in 2023).
- Revenue from Oman (ranked 9th for international revenue contribution) fell by 31% y-y in 4Q24 due to the high base revenue in 4Q23.
- There was no update on the timeline for the announcement of the approved hospital list for Kuwaiti patients. Management updated that the Kuwaiti government has halted funding support for healthcare outside of public hospitals, implying that patients are now self-pay for private hospitals within the country or for overseas treatments.
- Management mentioned that BH has renewed the contracts with UAE's independent institutions after changing the referral system from centralized to decentralized. This suggests a potential return of UAE patients in 2025.
- Revenue from Thai patients grew by 10% y-y in 4Q24, driven mainly by price adjustments and revenue intensity. BH also mentioned that there was a higher conversion rate from health check-up patients to hospital inpatients during 4Q24.
- There is a medical price adjustment of 4% in 2025 (vs 6% in 2024).
- Management expects revenue in 1Q25 to decline by 5% y-y following the high base of Kuwaiti patient revenue and an earlier Ramadan this year from 1-31 March 2025 (vs 11 March to 9 April 2024 last year).

Recommendation

No further negative news emerged from the analyst meeting. Although 1Q25 operations remain weak, BH's low 2H24 revenue creates a favorable base for potential growth in 2H25. Thus, we suggest investors keep BH on their radar due to the cheap valuation of 20x 2025E P/E.

KEY STOCK DATA

YE Dec (THB m)	2024	2025E	2026E	2027E
Revenue	25,718	26,319	27,780	29,181
Net profit	7,775	7,906	8,080	8,511
EPS (THB)	9.77	9.93	10.15	10.70
vs Consensus (%)	-	5.2	5.1	7.7
EBITDA	10,265	10,598	11,044	11,671
Recurring net profit	7,798	7,906	8,080	8,511
Core EPS (THB)	9.80	9.93	10.15	10.70
Chg. In EPS est. (%)	nm	0.0	0.0	nm
EPS growth (%)	12.7	1.4	2.2	5.3
Core P/E (x)	20.0	19.7	19.3	18.3
Dividend yield (%)	2.6	2.6	3.0	3.1
EV/EBITDA (x)	14.0	13.2	12.4	11.4
Price/book (x)	5.7	5.0	4.5	4.0
Net debt/Equity (%)	(43.1)	(48.9)	(53.9)	(57.7)
ROE (%)	30.4	26.8	24.4	23.3



Share price performance	1 Month	3 Month	12 Month
Absolute (%)	12.7	(7.3)	(14.6)
Relative to country (%)	24.5	14.1	(1.2)
Mkt cap (USD m)			4,598
3m avg. daily turnover (USD m)			23.7
Free float (%)			65
Major shareholder		Thai N\	/DR (13%)
12m high/low (THB)		284	.00/171.50
Issued shares (m)			922.70

Sources: Bloomberg consensus; FSSIA estimates



Teerapol Udomvej, CFA
Fundamental Investment Analyst on Securities; License no. 080523
teerapol.udo@fssia.com, +66 2646 9969

Recap: 4Q24 results review

- BH reported a core profit of THB1.9b (+11% y-y, -5% q-q) in 4Q24, beating our estimate by 7% mainly due to higher-than-expected Thai patient revenue and a lower tax rate from the BOI.
- Revenue fell 1% y-y, slightly better than our expectation, as Thai patient revenue grew by 10% y-y. However, international patient revenue fell by 6% y-y.
- As a result, the revenue contribution from Thai patients was 36% and international patients was 64 % (vs 32%:68% in 3Q23).
- COGS declined by 2% and SG&A was flat y-y thanks to better cost control. Thus, the EBITDA margin improved to 37% (vs 36% in 4Q23). Depreciation was also flat y-y.
- Tax expenses decreased by 32% y-y in 4Q24 to THB279m (vs THB408m in 4Q23) thanks to the lower tax rate of 13% (vs 19% in 4Q23) following tax benefits from the Investment Promotion for Community and Society Development by the BOI.
- 2024 core profit grew by 13% y-y to THB7.8b and accounted for 102% of our 2024 forecast of THB7.7b.
- BH announced a 2H24 dividend of THB3/shr. Combined with the 1H24 dividend of THB2/shr, it would imply a 3% dividend yield.

Exhibit 1: BH - 4Q24 results summary

	4Q23	1Q24	2Q24	3Q24	4Q24	Char	nge	2024	Change
	(THB m)	(q-q %)	(y-y %)	(THB m)	(y-y %)				
Sales	6,516	6,537	6,303	6,405	6,473	1	(1)	25,718	1
COGS (incl. depreciation)	(3,332)	(3,146)	(3,008)	(3,089)	(3,259)	5	(2)	(12,503)	(3)
Gross profit	3,184	3,391	3,294	3,316	3,214	(3)	1	13,215	6
SG&A	(1,140)	(1,020)	(1,007)	(1,003)	(1,142)	14	0	(4,171)	(0)
Operating profit	2,044	2,371	2,288	2,313	2,072	(10)	1	9,043	9
Net other income	29	29	28	41	46	12	58	145	31
Interest income	49	61	79	74	66	(11)	35	279	98
Interest expense	(1)	(2)	(2)	(2)	(2)	(3)	85	(8)	248
Pretax profit	2,121	2,459	2,393	2,426	2,182	(10)	3	9,459	11
Income Tax	(408)	(469)	(432)	(424)	(279)	(34)	(32)	(1,604)	1
Share gain/loss from JV	(0)	(0)	(0)	(0)	(0)				
Share gain/loss from associates	(0)	(0)	(0)	(0)	(0)			(0)	(94)
Minority interest	(11)	(15)	(24)	(12)	(7)	(44)	(40)	(57)	18
Core profit	1,702	1,975	1,937	1,990	1,896	(5)	11	7,798	13
Extraordinaries, GW & FX	19	10	(5)	(34)	7			(23)	
Reported net profit	1,721	1,985	1,932	1,955	1,903	(3)	11	7,775	11
Outstanding shares (m)	796	796	796	796	796	0	0	796	0
Core EPS (THB)	2.14	2.48	2.43	2.50	2.38	(5)	11	9.80	13
EPS (THB)	2.16	2.49	2.43	2.46	2.39	(3)	11	9.77	11
COGS (excl. depreciation)	3,058	2,879	2,742	2,820	2,984	6	(2)	11,426	(3)
Depreciation	274	267	267	269	275	2	0	1,077	(2)
EBITDA	2,348	2,667	2,582	2,623	2,393	(9)	2	10,265	8
Key ratios	(%)	(%)	(%)	(%)	(%)	(ppt)	(ppt)	(%)	(ppt)
Gross margin	49	52	52	52	50	(2)	1	51	2
SG&A/Revenue	17	16	16	16	18	2	0	16	(0)
EBITDA margin	36	41	41	41	37	(4)	1	40	2
Net profit margin	26	30	31	31	29	(1)	3	30	3
Operating stats	(y-y %)								
Hospital revenue growth	9	8	4	(5)	(3)				
OPD revenue growth	2	8	9	0	0				
IPD revenue growth	16	8	0	0	0				
International patient revenue growth	12	7	5	(7)	(5)				
Thai patient revenue growth	3	9	2	(1)	(0)				

Sources: BH; FSSIA estimates

Financial Statements

Bumrungrad Hospital

Profit and Loss (THB m) Year Ending Dec	2023	2024	2025E	2026E	2027E
Revenue	25,376	25,718	26,319	27,780	29,181
Cost of goods sold	(12,895)	(12,503)	(12,715)	(13,603)	(14,264)
Gross profit	12,481	13,215	13,604	14,176	14,918
Other operating income	111	145	149	154	158
Operating costs	(4,180)	(4,171)	(4,243)	(4,534)	(4,733)
Operating EBITDA	9,509	10,265	10,598	11,044	11,671
Depreciation	(1,097)	(1,077)	(1,088)	(1,248)	(1,328)
Goodwill amortisation	-	-	-	-	
Operating EBIT	8,412	9,188	9,511	9,796	10,343
Net financing costs	139	271	175	246	315
Associates	(1)	0	0	0	0
Recurring non-operating income	(1)	0	0	0	0
Non-recurring items Profit before tax	88	(23) 9,436	0 9,686	0	40.659
Tax	8,638 (1,583)	(1,604)	(1,719)	10,043 (1,898)	10,658 (2,078)
Profit after tax	7,055	7,832	7,966	8,145	8,580
Minority interests	(49)	(57)	(61)	(64)	(68)
Preferred dividends	(+3)	(01)	(01)	(0+)	(50)
Other items	_	-	_	_	_
Reported net profit	7,006	7,775	7,906	8,080	8,511
Non-recurring items & goodwill (net)	(88)	23	0	0	0
Recurring net profit	6,918	7,798	7,906	8,080	8,511
Per share (THB)					
Recurring EPS *	8.69	9.80	9.93	10.15	10.70
Reported EPS	8.80	9.77	9.93	10.15	10.70
OPS .	3.69	5.15	5.00	5.96	6.09
Diluted shares (used to calculate per share data)	796	796	796	796	796
Growth					
Revenue (%)	22.5	1.3	2.3	5.5	5.0
Operating EBITDA (%)	33.4	8.0	3.2	4.2	5.7
Operating EBIT (%)	40.0	9.2	3.5	3.0	5.6
Recurring EPS (%)	40.0	12.7	1.4	2.2	5.3
Reported EPS (%)	41.9	11.0	1.7	2.2	5.3
Operating performance					
Gross margin inc. depreciation (%)	49.2	51.4	51.7	51.0	51.1
Gross margin exc. depreciation (%)	53.5	55.6	55.8	55.5	55.7
Operating EBITDA margin (%)	37.5	39.9	40.3	39.8	40.0
Operating EBIT margin (%)	33.1	35.7	36.1	35.3	35.4
Net margin (%) Effective tax rate (%)	27.3 18.5	30.3 17.0	30.0 17.8	29.1 18.9	29.2 19.5
Dividend payout on recurring profit (%)	18.5 42.5	52.6	50.3	18.9 58.7	19.5 57.0
nterest cover (X)	(60.7)	(33.9)	(54.3)	(39.8)	(32.8)
nventory days	10.6	11.5	11.3	11.0	11.1
Debtor days	50.8	59.5	55.2	52.3	49.8
Creditor days	33.5	35.6	36.4	35.6	35.9
Operating ROIC (%)	52.9	54.7	54.4	54.6	56.8
ROIC (%)	51.0	49.1	46.1	46.3	48.2
ROE (%)	31.8	30.4	26.8	24.4	23.3
ROA (%)	25.6	24.7	22.6	20.6	19.7
* Pre-exceptional, pre-goodwill and fully diluted					
Revenue by Division (THB m)	2023	2024	2025E	2026E	2027E
Thai patient revenue	8,348	8,581	8,925	9,282	0
International patient revenue	16,948	17,053	17,311	18,414	0
Other revenue	80	83	83	83	29,181

Sources: Bumrungrad Hospital; FSSIA estimates

Financial Statements

Bumrungrad Hospital

Cash Flow (THB m) Year Ending Dec	2023	2024	2025E	2026E	2027E
Recurring net profit	6,918	7,798	7,906	8,080	8,511
Depreciation	1,097	1,077	1,088	1,248	1,328
Associates & minorities	- (40)	-	-	-	-
Other non-cash items	(16)	(1,846)	61 69	64 185	68 169
Change in working capital Cash flow from operations	(1,021) 6,978	(56) 6,973	9,123	9,577	10,077
Capex - maintenance	(1,617)	(1,380)	(1,579)	(1,389)	(1,751)
Capex - new investment	-	-	-	-	(., ,
Net acquisitions & disposals	(12)	(117)	0	0	0
Other investments (net)	-	-	-	-	
Cash flow from investing	(1,629)	(1,497)	(1,579)	(1,389)	(1,751)
Dividends paid	(2,938)	(4,101)	(3,979)	(4,743)	(4,848)
Equity finance	0	0	0	0	(
Debt finance	28	48	0	0 0	(
Other financing cash flows Cash flow from financing	31 (2,880)	(55) (4,108)	0 (3,979)	(4,743)	(4,848
lon-recurring cash flows	(2,880)	(4,100)	(3,979)	(4,743)	(4,040
Other adjustments	0	0	0	0	(
Net other adjustments	0	0	0	0	(
Movement in cash	2,469	1,368	3,565	3,444	3,478
Free cash flow to firm (FCFF)	5,351.60	5,484.09	7,611.50	8,255.00	8,393.01
Free cash flow to equity (FCFE)	5,407.78	5,469.17	7,544.33	8,187.84	8,325.8
Per share (THB)					
FCFF per share	5.80	5.94	8.25	8.95	9.10
FCFE per share	5.86	5.93	8.18	8.87	9.02
Recurring cash flow per share	10.05	8.83	11.38	11.80	12.45
Balance Sheet (THB m) Year Ending Dec	2023	2024	2025E	2026E	2027E
Fangible fixed assets (gross) Less: Accumulated depreciation	27,899 (14,921)	28,832 (15,503)	30,411 (16,591)	31,800 (17,839)	33,551 (19,167)
Tangible fixed assets (net)	12,978	13,328	13,819	13,961	14,383
ntangible fixed assets (net)	61	60	60	60	60
Long-term financial assets	-	-	-	-	
nvest. in associates & subsidiaries	13	130	130	130	130
Cash & equivalents	10,745	12,113	15,679	19,123	22,601
A/C receivable	4,408	3,982	3,982	3,982	3,982
nventories	362	356	362	385	403
Other current assets	169	280	286	302	318
Current assets	15,685	16,732	20,310	23,793	27,304
Other assets	475	2,403	2,403	2,403	2,403
Total assets	29,212	32,653	36,723	40,347	44,281
Common equity Minorities etc.	23,801 297	27,488 313	31,414 374	34,751 438	38,415 507
Total shareholders' equity	24,098	27,801	31,789	35,190	38,921
Long term debt	91	139	139	139	139
Other long-term liabilities	856	923	923	923	923
Long-term liabilities	947	1,062	1,062	1,062	1,062
A/C payable	1,078	1,149	1,169	1,242	1,301
Short term debt	0	0	0	0	(
Other current liabilities	3,089	2,641	2,703	2,853	2,997
Current liabilities	4,167	3,790	3,872	4,095	4,297
Total liabilities and shareholders' equity	29,212	32,653	36,723	40,347	44,281
Net working capital	772	828	759	575	400
Invested capital * Includes convertibles and preferred stock which is beir	14,299	16,750	17,172	17,129	17,383
<u> </u>	.9				
Per share (THB)	20.04	0.4.5.4	00.40	40.07	40.00
Book value per share Fangible book value per share	29.91 29.83	34.54 34.47	39.48 39.40	43.67 43.59	48.27 48.20
Financial strength	29.03	34.47	39.40	43.39	40.20
Net debt/equity (%)	(44.2)	(//3 1)	(48.0)	(53.0)	/57 7
Net debt/total assets (%)	(44.2) (36.5)	(43.1) (36.7)	(48.9) (42.3)	(53.9) (47.1)	(57.7 (50.7
Current ratio (x)	3.8	4.4	5.2	5.8	6.4
CF interest cover (x)	(38.0)	(19.2)	(42.1)	(32.2)	(25.4
Valuation	2023	2024	2025E	2026E	2027E
Recurring P/E (x) * Recurring P/E @ target price (x) *	22.5 25.3	20.0 22.5	19.7 22.1	19.3 21.7	18.3 20.0
Reported P/E (x)	22.2	20.0	19.7	19.3	18.3
Dividend yield (%)	1.9	2.6	2.6	3.0	3.
Price/book (x)	6.5	5.7	5.0	4.5	4.0
HCE/DOOK (X)		5.7	5.0	4.5	4.
Price/tangible book (x)	6.6	5.7	0.0		
* *	6.6 15.3	14.0	13.2	12.4	
Price/tangible book (x)					11.4 13.1

Sources: Bumrungrad Hospital; FSSIA estimates

Bumrungrad Hospital PCL (BH TB)

FSSIA ESG rating

★ ★ ★

Exhibit 2: FSSIA ESG score implication

51.21 /100

Rating	Score	Implication
****	>79-100	Leading its industry peers in managing the most significant ESG risks which not only better cost efficiency but also lead to higher profitability.
***	>59-79	A mixed track record of managing the most significant ESG risks and opportunities relative to industry peers.
***	>39-59	Relevant ESG materiality matrix has been constructively addressed, well-managed and incorporated into day-to-day operations, in which targets and achievements are evaluated annually.
**	>19-39	Relevant ESG materiality matrix has been identified with key management in charge for progress to be followed up on and to provide intensive disclosure. Most targets are conventional and achievable.
*	1-19	The company has adopted the United Nations Sustainable Development Goals (UN SDGs), established sustainability management guidelines and fully complies with regulations or ESG suggested guidance from related organizations such as the SET and SEC.

Sources: FSSIA estimates

Exhibit 3: ESG – peer comparison

	FSSIA			Domesti	c ratings					Glo	bal ratings			Bloomberg	
	ESG score	DJSI	SET ESG	ESG Rating	CG score	AGM level	Thai CAC	Morningstar ESG risk	ESG Book	MSCI	Moody's	Refinitiv	S&P Global	ESG score	Disclosure score
SET100	69.20	5.34	4.40	4.40	4.76	4.65	3.84	Medium	51.76	BBB	20.87	58.72	63.91	3.72	28.17
Coverage	67.12	5.11	4.15	4.17	4.83	4.71	3.53	Medium	52.04	BB	16.97	56.85	62.09	3.40	31.94
BCH	39.71				4.00	5.00	Certified	High	48.21			27.19	18.00	3.52	47.60
BDMS	74.00	Υ	Υ	Y	5.00	4.00		Medium	61.06	AA	34.00	59.83	72.00	3.45	58.92
ВН	51.21				4.00	4.00		Medium	64.29	Α	29.00	59.03	27.00	5.08	47.79
CHG	38.25				4.00	5.00		High	55.35			59.57	21.00	2.34	50.24
PR9	54.08		Υ	Y	5.00	5.00	Certified	High	71.12			62.39		2.43	37.90
PRINC	18.00				4.00	4.00	Certified								
RAM	11.75				3.00			High							
THG	18.75	-			5.00	5.00		High							
VIBHA	20.88				4.00	3.00	Declared	High					17.00		

Sources: SETTRADE.com; FSSIA's compilation

Exhibit 4: ESG score by Bloomberg

FY ending Dec 31	FY 2015	FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022
ESG financial materiality scores - ESG score	0.85	1.30	1.60	1.49	1.73	3.35	3.58	5.08
BESG environmental pillar score	0.00	1.75	1.75	1.75	1.75	3.21	3.73	3.73
BESG social pillar score	0.18	0.18	0.38	0.38	0.85	3.19	3.25	6.43
BESG governance pillar score	3.25	3.57	4.35	3.81	3.55	3.73	4.07	3.97
ESG disclosure score	31.24	32.94	35.78	35.78	36.40	47.68	47.79	47.79
Environmental disclosure score	0.42	5.53	8.91	8.91	9.76	35.43	35.76	35.76
Social disclosure score	12.03	12.03	17.17	17.17	18.20	26.39	26.39	26.39
Governance disclosure score	81.10	81.10	81.10	81.10	81.10	81.10	81.10	81.10
Environmental								
Emissions reduction initiatives	No	No	No	No	No	Yes	Yes	Yes
Climate change policy	No	No	No	No	No	Yes	Yes	Yes
Climate change opportunities discussed	No							
Risks of climate change discussed	No	No	No	No	No	No	Yes	Yes
GHG scope 1	_	_	_	_	_	_	_	_
GHG scope 2 location-based	_	_	_	_	_	_	_	_
GHG Scope 3	_	_	_	_	_	_	_	_
Carbon per unit of production	_	_	_	_	_	_	_	_
Biodiversity policy	No							
Energy efficiency policy	Yes							
Total energy consumption	_	0	0	0	0	0	0	0
Renewable energy use	_	_	_	_	_	_	_	_
Electricity used	_	_	_	_	_	_	_	_
Fuel used - natural gas	_	_	_	_	_	_	_	_

 $Sources: Bloomberg; FSSIA's \ compilation$

Exhibit 5: ESG score by Bloomberg (cont.)

FY ending Dec 31	FY 2015	FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022
Fuel used - crude oil/diesel	No							
Waste reduction policy	No	No	No	No	No	Yes	Yes	Yes
Hazardous waste	_	_	_	_	_	_	_	
Total waste	_	_	_	_	_	_	_	
Waste recycled	_	_	_	_	_	_	_	_
Waste sent to landfills	_	_	_	_	_	_	_	_
Environmental supply chain management	No	No	No	No	No	Yes	Yes	Yes
Water policy	No	No	No	No	Yes	Yes	Yes	Yes
Water consumption	_	_	_	_	_	_	_	_
Social								
Human rights policy	Yes							
Policy against child labor	No	No	No	No	Yes	Yes	Yes	Yes
Quality assurance and recall policy	No	No	No	No	No	Yes	Yes	Yes
Consumer data protection policy	No	No	No	No	No	Yes	Yes	Yes
Equal opportunity policy	Yes							
Gender pay gap breakout	No							
Pct women in workforce	_	_	_	_	_	_	_	_
Pct disabled in workforce	_	_	_	_	_	_	_	_
Business ethics policy	No	No	No	No	No	Yes	Yes	Yes
Anti-bribery ethics policy	Yes							
Health and safety policy	Yes							
Lost time incident rate - employees	_	_	_	_	_	_	_	_
Total recordable incident rate - employees	_	_	_	_	_	_	_	_
Training policy	Yes							
Fair remuneration policy	No							
Number of employees – CSR	_	_	3,984	3,980	4,088	3,782	3,455	4,219
Employee turnover pct	_	_	_	_	_	7	7	8
Total hours spent by firm - employee training	_	_	247,805	268,252	283,707	207,353	195,380	234,480
Social supply chain management	No	No	No	No	No	Yes	Yes	Yes
Governance								
Board size	11	11	11	11	10	10	11	11
No. of independent directors (ID)	4	4	4	4	4	4	5	
No. of women on board	3	3	3	3	3	3	3	3
No. of non-executive directors on board	8	8	9	9	9	9	10	10
Company conducts board evaluations	Yes							
No. of board meetings for the year	5	4	6	4	4	7	4	4
Board meeting attendance pct	91	93	97	87	88	87	95	98
Board duration (years)	3	3	3	3	3	3	3	;
Director share ownership guidelines	No							
Age of the youngest director	42	43	49	50	51	52	27	28
Age of the oldest director	75	75	78	79	79	80	78	79
No. of executives / company managers	7	6	6	6	4	4	4	
No. of female executives	1	2	2	3	3	3	3	;
Executive share ownership guidelines	No							
Size of audit committee	3	3	3	3	3	3	4	4
No. of ID on audit committee	3	3	3	3	3	3	4	4
Audit committee meetings	4	4	4	5	5	4	4	4
Audit meeting attendance %	100	92	92	87	100	100	87	100
Size of compensation committee	3	3	3	3	3	3	3	
No. of ID on compensation committee	1	1	1	1	1	1	1	1
No. of compensation committee meetings	1	1	5	3	2	2	3	3
Compensation meeting attendance %	100	100	100	100	100	83	100	100
Size of nomination committee	3	3	3	3	3	3	3	100
No. of nomination committee meetings	1	1	5	3	2	2	3	
Nomination meeting attendance %	100	100	100	100	100	83	100	100
Sustainability governance	100	100	100	100	100		100	100

Sources: Bloomberg; FSSIA's compilation

Disclaimer for ESG scoring

ESG score	Methodolog	ly			Rating						
The Dow Jones Sustainability Indices (DJSI) By S&P Global	process bas from the ann	ed on the compa nual S&P Global	nsparent, rules-based anies' Total Sustainabil Corporate Sustainabili ies within each industr	ity Scores resulting ty Assessment (CSA).	Sustainability A ESG Score of I scoring compa selected from t	ssessment (C ess than 45% ny are disqual ne Eligible Un		ompanies with al ESG Score uents of the D	an S&P Globa of the highest JSI indices are		
SET ESG Ratings List (SETESG) by The Stock Exchange of Thailand (SET)	managing bin Candidates 1) no irregul float of >150 up capital. S 70%; 2) inde wrongdoing	usiness with tran must pass the pr ar trading of the shareholders, a ome key disqual ependent director related to CG, so	sibility in Environmental sparency in Governan- eemptive criteria, with board members and ex- ind combined holding in lifying criteria include: and free float violatic pocial & environmental in nings in red for > 3 year	ce, updated annually. two crucial conditions: kecutives; and 2) free nust be >15% of paid- 1) CG score of below on; 3) executives' mpacts; 4) equity in	nature of the relevant industry and materiality.						
CG Score by Thai nstitute of Directors Association (Thai IOD)	annually by Thailand (SI	the Thai IOD, wit	n sustainable developr th support from the Sto are from the perspectiv	ck Exchange of	Good (80-89), and not rated for equitable treatr	3 for Good (70 or scores belo nent of sharel (5%); 4) disclo	ories: 5 for Excel 0-79), 2 for Fair (6 w 50. Weightings nolders (weight 2 ssure & transpare	60-69), 1 for P s include: 1) th 5% combined	ass (60-69), le rights; 2) and); 3) the role of		
AGM level By Thai Investors Association (TIA) with support from the SEC	treatment ar transparent out of five th criteria cove date (45%), circulation of s exercised. The and verifiability	e incorporated ir and sufficiently de e CG component r AGM procedure and after the me sufficient information e second assesses y; and 3) openness	es before the meeting (eeting (10%). (The first a. n for voting; and 2) facilitati 1) the ease of attending m	s and information is ortant elements of two ually. The assessment (45%), at the meeting ssesses 1) advance ing how voting rights can be eetings; 2) transparency is the meeting minutes that			ofour categories: (80-89), and not				
Fhai CAC By Thai Private Sector Collective Action Against Corruption CAC)	establishme policies. The (Companies of Declaration of Certification, in managers and	nt of key controls c Certification is of eciding to become of Intent to kick off an including risk assess	ecklist include corrupties, and the monitoring a good for three years. a CAC certified member standard the subsement, in place of policy are itshment of whistleblowing takeholders.)	and developing of art by submitting a mit the CAC Checklist for ad control, training of	passed Checkl	st will move for se members a	ed by a committe or granting certific re twelve highly i ichievements.	cation by the 0	CAC Council		
Morningstar Sustainalytics	based on an risk is unma regulatory filin	assessment of l naged. Sources to gs, news and other	rating provides an ove how much of a compar be reviewed include corp media, NGO reports/webs	ny's exposure to ESG orate publications and sites, multi-sector			score is the sum higher ESG risk		ed risk. The		
		ompany feedback, l uality & peer review	ESG controversies, issuer : /s.	feedback on draft ESG	0-10	10-20	20-30	30-40	40+		
ESG Book	positioned to the principle helps explai over-weighti	o outperform ove of financial mate n future risk-adju	stainable companies the rithe long term. The meriality including inform isted performance. Mathigher materiality and basis.	ethodology considers ation that significantly teriality is applied by	The total ESG scores using m	score is calculateriality-base	ated as a weight d weights. The s ndicating better p	ed sum of the core is scaled	features		
<u>MSCI</u>				anagement of financially their exposure to ESG ris					nethodology to		
	AAA	8.571-10.000									
	AA	7.143-8.570	Leader:	leading its industry in m	anaging the most s	gnificant ESG ri	sks and opportunitie	es			
	Α	5.714-7.142									
	BBB	4.286-5.713	Average:	a mixed or unexceptional industry peers	al track record of m	anaging the mos	st significant ESG ris	sks and opportu	nities relative to		
	ВВ	2.857-4.285		7.							
	В	1.429-2.856	Laggard:	lagging its industry base	ad on its high aveca	ure and failure t	o manage significan	nt ESG ricks			
	ccc	0.000-1.428	Layyaru.	ayyiny ito industry base		ure ariu idilule l	——————	IL LOG IISKS			
Moody's ESG solutions	believes tha	t a company inte		take into account ESG o to its business model and medium to long term.							
Refinitiv ESG rating	based on pu	blicly available a	and auditable data. The	a company's relative ES score ranges from 0 to re 0 to 25 = poor; >25 to 50	100 on relative E	SG performar	nce and insufficie	nt degree of t			
S&P Global				suring a company's perfo sification. The score ran			of ESG risks, op	portunities, ar	d impacts		
Bloomberg	ESG Score	s	core is based on Bloor	ating the company's aggi nberg's view of ESG fina the weights are determin	ncial materiality.	The score is	a weighted gene	ralized mean (power mean)		

Rating regarding the sustainable development of Thai listed companies, both on the SET and MAI, are publicly available on the website of the Securities and Exchange Commission of Thailand (SEC). Currently, ratings available are 1) "CG Score"; 2) "AGM Level"; 3) "Thai CAC"; and 4) THSI. The ratings are updated on an annual basis. FSSIA does not confirm nor certify the accuracy of such ratings.

Source: FSSIA's compilation

GENERAL DISCLAIMER

ANALYST(S) CERTIFICATION

Teerapol Udomvej, CFA FSS International Investment Advisory Securities Co., Ltd

The individual(s) identified above certify(ies) that (i) all views expressed in this report accurately reflect the personal view of the analyst(s) with regard to any and all of the subject securities, companies or issuers mentioned in this report; and (ii) no part of the compensation of the analyst(s) was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed herein.

This report has been prepared by FSS International Investment Advisory Securities Company Limited (FSSIA). The information herein has been obtained from sources believed to be reliable and accurate; however FSSIA makes no representation as to the accuracy and completeness of such information. Information and opinions expressed herein are subject to change without notice. FSSIA has no intention to solicit investors to buy or sell any security in this report. In addition, FSSIA does not guarantee returns nor price of the securities described in the report nor accept any liability for any loss or damage of any kind arising out of the use of such information or opinions in this report. Investors should study this report carefully in making investment decisions. All rights are reserved.

This report may not be reproduced, distributed or published by any person in any manner for any purpose without permission of FSSIA. Investment in securities has risks. Investors are advised to consider carefully before making investment decisions.

History of change in investment rating and/or target price



Date	Rating	Target price	Date	Rating	Target price	Date	Rating	Target price
09-May-2022 01-Jul-2022 22-Aug-2022 10-Nov-2022	BUY BUY BUY BUY	205.00 210.00 235.00 255.00	21-Feb-2023 09-May-2023 17-Aug-2023 05-Mar-2024	BUY BUY BUY BUY	260.00 280.00 300.00 305.00	03-May-2024 07-Nov-2024 24-Feb-2025	BUY HOLD BUY	310.00 285.00 220.00

Teerapol Udomvej, CFA started covering this stock from 30-Jul-2020

Price and TP are in local currency

Source: FSSIA estimates

Company	Ticker	Price	Rating	Valuation & Risks
Bumrungrad Hospital	ВН ТВ	THB 195.50	BUY	Downside risks to our DCF-based target price include 1) a slowdown in international patients due to economic concerns, political protests or floods; 2) regulatory risks from drug prices and medical bill controls; and 3) higher medical fee discount promotions, leading to a weaker EBITDA margin.

Source: FSSIA estimates

Additional Disclosures

Target price history, stock price charts, valuation and risk details, and equity rating histories applicable to each company rated in this report is available in our most recently published reports. You can contact the analyst named on the front of this note or your representative at Finansia Syrus Securities Public Company Limited.

All share prices are as at market close on 04-Mar-2025 unless otherwise stated.

RECOMMENDATION STRUCTURE

Stock ratings

Stock ratings are based on absolute upside or downside, which we define as (target price* - current price) / current price.

BUY (B). The upside is 10% or more.

HOLD (H). The upside or downside is less than 10%.

REDUCE (R). The downside is 10% or more.

Unless otherwise specified, these recommendations are set with a 12-month horizon. Thus, it is possible that future price volatility may cause a temporary mismatch between upside/downside for a stock based on market price and the formal recommendation.

* In most cases, the target price will equal the analyst's assessment of the current fair value of the stock. However, if the analyst doesn't think the market will reassess the stock over the specified time horizon due to a lack of events or catalysts, then the target price may differ from fair value. In most cases, therefore, our recommendation is an assessment of the mismatch between current market price and our assessment of current fair value.

Industry Recommendations

Overweight. The analyst expects the fundamental conditions of the sector to be positive over the next 12 months.

Neutral. The analyst expects the fundamental conditions of the sector to be maintained over the next 12 months.

Underweight. The analyst expects the fundamental conditions of the sector to be negative over the next 12 months.

Country (Strategy) Recommendations

Overweight (O). Over the next 12 months, the analyst expects the market to score positively on two or more of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Neutral (N). Over the next 12 months, the analyst expects the market to score positively on one of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Underweight (U). Over the next 12 months, the analyst does not expect the market to score positively on any of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.